Randox unveils Evidence RABTA
July 7, 2025—Randox has launched the Evidence RABTA (random access biochip technology analyzer), capable of processing up to 60 samples per hour and delivering up to 2,640 test results per hour.
Webinars and Sponsored Roundtables — Register Now
Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
CAP TODAY
FDA approves Oncomine Dx Express as CDx for Zegfrovy
July 3, 2025—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Express test on the Ion Torrent Genexus Dx integrated sequencer as an in vitro diagnostic assay for use as a companion diagnostic for Dizal’s Zegfrovy (sunvozertinib) to identify patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
Gold Standard Diagnostics
Gold Standard Diagnostics is a global leader in diagnostic solutions, offering automated platforms and a comprehensive test menu across virology, bacteriology, parasitology, mycology, hormones and autoimmune diseases. We specialize in automated RPR Syphilis testing and open platforms for ELISA & CLIA.
FDA clears AISight Dx for primary diagnosis
July 1, 2025—PathAI has received 510(k) clearance from the U.S. Food and Drug Administration for its AISight Dx digital pathology image-management system for use in primary diagnosis in clinical settings.
FDA OK’s Datroway for EGFR-mutated NSCLC
June 30, 2025—Datroway (datopotamab deruxtecan-dlnk) has been approved in the United States for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Bio-Rad presents workshops, demos, more at ADLM 2025
June 24, 2025—Bio-Rad Laboratories will present an array of clinical diagnostic-related offerings at this year’s Association for Diagnostics and Laboratory Medicine Clinical Lab Expo in Chicago, July 27–31.
Werfen
A Specialized Diagnostics leader, Werfen delivers innovative Hemostasis, Acute Care, Transfusion, Autoimmunity, Transplant and Immunoassay solutions to Power Patient Care. Key products: ACL TOP® Family 70 Series, HemosIL® assays, HemoHub®; GEM® Premier™ 7000
TELCOR
TELCOR is the proven leader of healthcare software solutions for point of care middleware and laboratory revenue cycle management software and services. Customers today need robust, efficient solutions to tackle laboratory and hospital challenges.
Streck
Established in 1971, Streck provides solutions that ensure every result counts by empowering clinical and research laboratories to reliably deliver accurate results, advance diagnostics and enable healthier, happier lives for patients everywhere.
Seegene Inc.
Seegene Inc., a global leader in multiplex PCR diagnostics, introduces CURECA™, a fully automated PCR platform offering true end-to-end automation from sample loading to result interpretation.